Loading…

Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy‐associated hepatitis in Japan

Background and Aim Immune checkpoint inhibitors (ICI) have revolutionized anti‐malignancy therapy and thus have been increasingly used. Although ICI may cause immune‐related adverse events (irAE) in various organs, including the liver, the prevalence and predictive factors of irAE have not been clar...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology and hepatology 2020-10, Vol.35 (10), p.1782-1788
Main Authors: Kitagataya, Takashi, Suda, Goki, Nagashima, Kazunori, Katsurada, Takehiko, Yamamoto, Koji, Kimura, Megumi, Maehara, Osamu, Yamada, Ren, Shigesawa, Taku, Suzuki, Kazuharu, Nakamura, Akihisa, Ohara, Masatsugu, Umemura, Machiko, Kawagishi, Naoki, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, Ohnishi, Shunsuke, Komatsu, Yoshito, Hata, Hiroo, Takeuchi, Satoshi, Abe, Takashige, Sakakibara‐Konishi, Jun, Teshima, Takanori, Homma, Akihiro, Sakamoto, Naoya
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aim Immune checkpoint inhibitors (ICI) have revolutionized anti‐malignancy therapy and thus have been increasingly used. Although ICI may cause immune‐related adverse events (irAE) in various organs, including the liver, the prevalence and predictive factors of irAE have not been clarified. Methods In this retrospective study, consecutive patients who had malignancies and were treated with ICI without other chemotherapeutic agents at Hokkaido University Hospital between 2014 and 2019 were screened. Patients were excluded if they were
ISSN:0815-9319
1440-1746
DOI:10.1111/jgh.15041